Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Featured trial
Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE)

This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy.

cabozantinib
transurethral resection of bladder tumor
neuropathy
carcinoma
protein/creatinine ratio
  • 0 views
  • 16 Feb, 2024
  • 1 location
Featured trial
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer  

Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving CBM588, nivolumab, …

  • 0 views
  • 14 Mar, 2022
  • 1 location
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mutation or ALK translocation, who have progressed following treatment with platinum-containing chemotherapy and …

docetaxel
measurable disease
EGFR
cabozantinib
hepatitis
  • 0 views
  • 16 Feb, 2024
  • 98 locations
Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma

This is an open-label, single-center, Phase II trial designed to estimate in terms of PFS the efficacy of cabozantinib, given as second- or third- line treatment in HCC patients that progress on or are intolerant to immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 antibodies.

antiviral drugs
hepatitis
cabozantinib
TACE
renal function test
  • 0 views
  • 16 Feb, 2024
  • 1 location
Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

This phase I/II trial studies the side effects and best dose of cabozantinib when given with radiation therapy and how well it works in treating patients with sarcoma of the extremities. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

hair thinning
sarcoma
colony-stimulating factors
ct scan
bone metastases
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial

cabozantinib
hypertension
absolute neutrophil count
warfarin
activated partial thromboplastin time
  • 0 views
  • 16 Feb, 2024
  • 1 location